Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis
10.1182/blood-2018-02-832576
Saved in:
Main Authors: | Teoh, Phaik Ju, An, Omer, Chung, Tae-Hoon, Chooi, Jing Yuan, Toh, Sabrina HM, Fan, Shuangyi, Wang, Wilson, Koh, Bryan TH, Fullwood, Melissa J, Ooi, Melissa G, de Mel, Sanjay, Soekojo, Cinnie Y, Chen, Leilei, Ng, Siok Bian, Yang, Henry, Chng, Wee Joo |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Language: | English |
Published: |
AMER SOC HEMATOLOGY
2019
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/155188 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
Similar Items
-
Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis
by: Chong, Lip Leong, et al.
Published: (2021) -
ELUCIDATING THE ROLE OF ADAR1 IN REGULATING IMMUNOTHERAPEUTIC RESPONSE IN MULTIPLE MYELOMA
by: KOH MUN YEE
Published: (2023) -
CHARACTERIZING FUNCTIONAL ROLES AND CLINICAL IMPLICATIONS OF SUPER ENHANCER ASSOCIATED GENES IN MULTIPLE MYELOMA
by: XIONG SINAN
Published: (2024) -
Natural history and prognostic factors at first relapse in multiple myeloma
by: Wang, C., et al.
Published: (2021) -
Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma
by: Jia, Yunlu, et al.
Published: (2021)